Oncternal Therapeutics, Inc. (ONCT) SEC filings
ONCT SEC filings moved a median of +0.42% by the close. ONCT SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the ONCT overview →
25 measured ONCT SEC filing events.
Where these ONCT SEC filings landedvs 20 measured ONCT SEC filing reactions
| Middle 50% of ONCT SEC filing reactions | -8.68% to +1.22% |
|---|---|
| Median reaction (to close) | +0.42% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ONCT SEC filing events with a measured close landed between -8.68% and +1.22%; 60% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form EFFECT Oncternal Therapeutics, | SEC filing · Form EFFECT | — | — | |
| Form 15-12G Oncternal Therapeutics, | SEC filing · Form 15-12G | — | — | |
| Form POS AM Oncternal Therapeutics, | SEC filing · Form POS | — | — | |
| Form S-8 POS Oncternal Therapeutics, | SEC filing · Form S-8 | — | — | |
| Form 25 Oncternal Therapeutics, | SEC filing · Form 25 | — | — | |
| Form 8-K Oncternal Therapeutics, For: Nov 22 | SEC filing · Form 8-K | -4.16% | -14.46% | |
| Form 8-K Oncternal Therapeutics, For: Nov 13 | SEC filing · Form 8-K | +0.88% | +0.00% | |
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.54% | -19.88% | |
| Form 8-K Oncternal Therapeutics, For: Sep 11 | SEC filing · Form 8-K | -6.16% | -11.52% | |
| Form 10-Q Oncternal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -4.18% | -8.54% | |
| Form 8-K Oncternal Therapeutics, For: Aug 08 | SEC filing · Form 8-K | -4.18% | -8.54% | |
| Form 8-K Oncternal Therapeutics, For: Jun 20 | SEC filing · Form 8-K | +1.87% | +0.11% | |
| Form 10-Q Oncternal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | -9.12% | |
| Form 8-K Oncternal Therapeutics, For: May 09 | SEC filing · Form 8-K | — | -9.12% | |
| Form EFFECT Oncternal Therapeutics, | SEC filing · Form EFFECT | — | +9.04% | |
| Form ARS Oncternal Therapeutics, For: Dec 31 | SEC filing · Form ARS | +0.00% | +0.95% | |
| Form DEF 14A Oncternal Therapeutics, For: Jun 20 | SEC filing · Form DEF | +0.00% | +0.95% | |
| Form DEFA14A Oncternal Therapeutics, | SEC filing · Form DEFA14A | +0.00% | +0.95% | |
| Form S-3 Oncternal Therapeutics, | SEC filing · Form S-3 | — | +2.03% | |
| Form 10-K Oncternal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +3.90% | |
| Form 8-K Oncternal Therapeutics, For: Mar 07 | SEC filing · Form 8-K | +0.00% | +3.90% | |
| Form 8-K Oncternal Therapeutics, For: Jan 22 | SEC filing · Form 8-K | +1.40% | +31.13% | |
| Form 8-K Oncternal Therapeutics, For: Jan 03 | SEC filing · Form 8-K | -5.29% | +0.14% | |
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.92% | +0.69% | |
| Form 8-K Oncternal Therapeutics, For: Nov 09 | SEC filing · Form 8-K | +3.92% | +0.69% |
Keep exploring
More ONCT: earnings → · analyst actions → · ONCT overview →